½ÃÀ庸°í¼­
»óǰÄÚµå
1477244

¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀå : À¯Çüº°, ÀûÀÀÁõº°, À¯Åë ä³Îº°, Áö¿ªº°

Global Tobramycin Eye Drop Market, By Type, By Indication, By Distribution Channel, and Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀåÀº 2024³â¿¡´Â 10¾ï 1,890¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2031³â¿¡´Â 25¾ï 7,320¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2024³âºÎÅÍ 2031³â±îÁö CAGRÀº 14.1%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2023³â ½ÃÀå ±Ô¸ð(2024³â) 10¾ï 1,890¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031³â
¿¹Ãø±â°£(CAGR 2024-2031³â) 14.10% ±Ý¾× ¿¹Ãø(2031³â) 25¾ï 7,320¸¸ ´Þ·¯
±×¸². ¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ Áö¿ªº° ½ÃÀå Á¡À¯À²(%)(2024³â)
Global Tobramycin Eye Drop Market-IMG1

Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦´Â ¾Æ¹Ì³ë±Û¸®Äڽõå°è Ç×»ýÁ¦ÀÇ ¿Ü¿ë¾àÀ¸·Î, °¨¼ö¼ºÀÌ ³ôÀº ±×¶÷ À½¼º ¼¼±Õ¿¡ ÀÇÇÑ ¿Ü¾ÈºÎ °¨¿°ÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ¹ÚÅ׸®¾ÆÀÇ ´Ü¹éÁú ÇÕ¼ºÀ» ¾ïÁ¦ÇÏ¿© À¯ÇØÇÑ ¹ÚÅ׸®¾ÆÀÇ ¼ºÀåÀ» ¹æÁöÇÕ´Ï´Ù. ¿À·§µ¿¾È ÄÄÇ»ÅÍ »ç¿ë, ÄÜÅÃÆ®·»Áî Âø¿ë, ¾È°ú ¼ö¼ú µîÀÇ À§Çè ¿äÀÎÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾È±¸ °¨¿°ÀÇ À¯º´·üÀº Àü ¼¼°èÀûÀ¸·Î È®´ëµÇ°í ÀÖÀ¸¸ç, Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀåÀº ¾È ÁúȯÀÇ À¯º´·ü »ó½Â, ¾È Áúȯ¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸ Áõ°¡, ¾È°ú ÀÇ·á¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ¼ºÀåÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ´« ¿°Áõ, °á¸·¿° µî Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ÀÇ Àå±â°£ »ç¿ë°ú °ü·ÃµÈ ºÎÀÛ¿ë°ú °°Àº ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀÌ ÀúÇØµÉ ¼ö ÀÖ½À´Ï´Ù. Åäºê¶ó¸¶À̽ÅÀ» ÀÌ¿ëÇÑ ½Å±Ô ¾à¹°Àü´Þ¹ý°ú º´¿ë ¿ä¹ýÀÇ ¿¬±¸ °³¹ßÀÌ ÁøÇàµÇ°í ÀÖ¾î ½ÃÀå ÁøÃâ±â¾÷¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.

ÀÌ Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â ¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2023³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2024-2031³â) ½ÃÀå ±Ô¸ð(100¸¸ ´Þ·¯)¿Í º¹ÇÕ¿¬°£ ¼ºÀå·ü(CAGR%)À» °ÔÀçÇß½À´Ï´Ù.
  • ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾ÈÀÇ ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
  • ¿£ÅÍÇÁ¶óÀÌÁî ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¾÷Àû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀÌ ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀåÀº ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ Áö¿øÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû ¹× ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ ¹× ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • ÀϰüÇü ±âȸ ¸Ê(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦ ¹× µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ±âȸ
  • ¿µÇ⠺м®
  • ½ÃÀå µ¿Çâ
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Á¶¾÷ü ¼öÀÍ
  • Àμö ¹× Á¦ÈÞ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã ¹× ½ÂÀÎ
  • ÀÚ±Ý Á¶´Þ ¹× ÅõÀÚ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®

Á¦4Àå ¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀå : Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ÀüüÀûÀÎ ¿µÇâ
  • Á¤ºÎÀÇ ´ëó
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀå : À¯Çüº°(2019-2031³â)(100¸¸ ´Þ·¯)

  • ¼­¹®
  • Åäºê¶ó¸¶À̽Š¹× µ¦»ç¸ÞŸ¼Õ Çöʾ×
  • Åäºê¶ó¸¶À̽ŠÇöʾ×
  • ±âŸ

Á¦6Àå ¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀå : ÀûÀÀÁõº°(2019-2031³â)(100¸¸ ´Þ·¯)

  • ¼­¹®
  • ¼¼±Õ¼º ¾È°¨¿°Áõ
  • °¢¸·¿°
  • ¾È°ú ¼ö¼ú ÀüÈÄÀÇ ¿¹¹æ
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀå : À¯Åë ä³Îº°(2019-2031³â)(100¸¸ ´Þ·¯)

  • ¼­¹®
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°èÀÇ Åäºê¶ó¸¶À̽ŠÁ¡¾ÈÁ¦ ½ÃÀå : Áö¿ªº°(2019-2031³â)(100¸¸ ´Þ·¯)

  • ¼­¹®
  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN ±¹°¡
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • °ÉÇÁ Çù·Â ȸÀÇ
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • AdvaCare Pharma
    • Beye, LLC.
    • Grevis Pharmaceuticals Pvt Ltd.
    • Elvia Care Pvt Ltd
    • Novalab Healthcare
    • Zydus Group
    • Bausch Lomb
    • Hilbert Healthcare
    • Sanify Healthcare
    • Choroid Laboratories Private Limited.
    • Torainse Lifecare Pvt. Ltd.
    • Divine Laboratories Private Limited
    • Incepta Pharmaceuticals Ltd.
    • Alembic Pharmaceuticals Limited

Á¦10Àå ºÐ¼®°¡ Ãßõ

  • À¶¼º ¹× ¼èÅð
  • ÀϰüÇü ±âȸ ¸Ê

Á¦11Àå Âü°í ¹®Çå ¹× Á¶»ç ¹æ¹ý

  • Âü°í ¹®Çå
  • Á¶»ç ¹æ¹ý
AJY 24.05.20

Global tobramycin eye drop market is estimated to be valued at USD 1,018.9 Mn in 2024 and is expected to reach USD 2,573.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 14.1% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 1,018.9 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 14.10% 2031 Value Projection: US$ 2,573.2 Mn
Figure. Global Tobramycin Eye Drop Market Share (%), By Region 2024
Global Tobramycin Eye Drop Market - IMG1

Tobramycin eye drops are topical aminoglycoside antibiotics that are used for treating external eye infections caused by susceptible Gram-negative bacteria. These work by interfering with bacterial protein synthesis, thus, stopping the growth of harmful bacteria. The expanding prevalence of ocular infections globally due to increasing risk factors such as prolonged computer use, contact lens wear, eye surgeries, and others boosts demand for tobramycin eye drops

Market Dynamics:

Global tobramycin eye drop market has been witnessing growth due to factors such as rising prevalence of eye diseases, growing elderly population who are more prone to eye problems, increasing awareness about eye care. However, the market growth can be hindered due to factors such as side effects associated with long-term use of tobramycin eye drops like eye irritation, conjunctivitis, and others. Ongoing research and development for novel drug delivery methods and combination therapies using tobramycin offers lucrative opportunities for market players.

Key Features of the Study:

  • This report provides in-depth analysis of the global tobramycin eye drop market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global tobramycin eye drop market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study AdvaCare Pharma, Beye, LLC., Grevis Pharmaceuticals Pvt Ltd., Elvia Care Pvt Ltd, Novalab Healthcare, Zydus Group, Bausch + Lomb, Hilbert Healthcare, Sanify Healthcare, Choroid Laboratories Private Limited., Torainse Lifecare Pvt. Ltd., Divine Laboratories Private Limited, Incepta Pharmaceuticals Ltd., Alembic Pharmaceuticals Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • Global tobramycin eye drop market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tobramycin eye drop market.

Detailed Segmentation-

  • By Type:
    • Tobramycin and Dexamethasone Suspension
    • Tobramycin Suspension
    • Others Tobramycin Combinations
  • By Indication:
    • Bacterial Eye Infections
    • Keratitis
    • Pre-/post-ocular Surgery Prophylaxis
    • Others
  • By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Company Profiles:
    • AdvaCare Pharma
    • Beye, LLC.
    • Grevis Pharmaceuticals Pvt Ltd.
    • Elvia Care Pvt Ltd
    • Novalab Healthcare
    • Zydus Group
    • Bausch + Lomb
    • Hilbert Healthcare
    • Sanify Healthcare
    • Choroid Laboratories Private Limited.
    • Torainse Lifecare Pvt. Ltd.
    • Divine Laboratories Private Limited
    • Incepta Pharmaceuticals Ltd.
    • Alembic Pharmaceuticals Limited

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Type
    • Market Snapshot, By Indication
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Opportunities
  • Impact Analysis
  • Market Trends
  • Key Developments
  • Regulatory Scenario
  • Manufacturer Revenue
  • Acquisitions and Partnerships Scenario
  • Product Launches/Approvals
  • Funding and Investments
  • PEST Analysis
  • Porter's Analysis

4. Global Tobramycin Eye Drop Market- Impact of Coronavirus (COVID-19) Pandemic

  • Overall Impact
  • Government Initiatives
  • COVID-19 Impact on the market

5. Global Tobramycin Eye Drop Market, By Type, 2019 - 2031, (USD Mn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Tobramycin and Dexamethasone Suspension
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Tobramycin Suspension
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Others Tobramycin Combinations
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

6. Global Tobramycin Eye Drop Market, By Indication, 2019 - 2031, (USD Mn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Bacterial Eye Infections
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Keratitis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Pre-/post-ocular Surgery Prophylaxis
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Others
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

7. Global Tobramycin Eye Drop Market, By Distribution Channel, 2019 - 2031, (USD Mn)

  • Overview
    • Market Share Analysis, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, 2019 - 2031
    • Segment Trends
  • Hospital Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Retail Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)
  • Online Pharmacies
    • Overview
    • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Mn)

8. Global Tobramycin Eye Drop Market, By Region, 2019 - 2031, (USD Mn)

  • Introduction
    • Market Share Analysis, By Region, 2024 and 2031 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2031
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Mn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Mn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Company Profiles
    • AdvaCare Pharma*
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Beye, LLC.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Grevis Pharmaceuticals Pvt Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Elvia Care Pvt Ltd
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Novalab Healthcare
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Zydus Group
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Bausch + Lomb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Hilbert Healthcare
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Sanify Healthcare
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Choroid Laboratories Private Limited.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Torainse Lifecare Pvt. Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Divine Laboratories Private Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Incepta Pharmaceuticals Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies
    • Alembic Pharmaceuticals Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Market Strategies

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us and Sales Contact
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦